Literature DB >> 32828314

LncRNA Linc-PINT inhibits miR-523-3p to hamper retinoblastoma progression by upregulating Dickkopf-1 (DKK1).

Xiaoping Zhou1, Yongping Wang2, Qiang Li3, Dahui Ma4, Aiqing Nie3, Xiaoli Shen5.   

Abstract

Emerging evidences indicated that long non-coding RNAs (LncRNAs) regulated the pathogenesis of retinoblastoma (RB). However, up until now, the role of LncRNA Linc-PINT in the regulation of RB progression is still largely unknown. The present study identified LncRNA Linc-PINT as a tumor suppressor to hinder RB development by regulating miR-523-3p/Dickkopf-1 (DKK1) axis. Mechanistically, Linc-PINT was low-expressed, while miR-523-3p was high-expressed in RB cells, compared to the normal retinal epithelial cells (ARPE-19). Further gain- and loss-function experiments verified that both upregulation of Linc-PINT and miR-523-3p downregulation slowed down cell growth, invasion and migration, and promoted cell apoptosis in RB cells, but Linc-PINT ablation and miR-523-3p overexpression promoted malignant phenotypes in RB cells. In addition, the dual-luciferase reporter gene system and RNA pull-down assay validated that Linc-PINT positively regulated DKK1 expressions by sponging miR-523-3p, and Linc-PINT inhibited RB progression by regulating miR-523-3p/DKK1 axis. Functionally, we found that both miR-523-3p overexpression and DKK1 silence abrogated the anti-cancer effects of overexpressed Linc-PINT on RB cells. Finally, Linc-PINT inhibited tumorigenicity of RB cells in xenograft mice models. In general, analysis of the data suggested that Linc-PINT inhibited miR-523-3p to upregulate DKK1, resulting in the inhibition of RB, and we demonstrated that Linc-PINT and miR-523-3p could be utilized as potential diagnostic and therapeutic biomarkers for RB in clinic.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dickkopf-1; LncRNA Linc-PINT; Retinoblastoma; miR-523-3p

Mesh:

Substances:

Year:  2020        PMID: 32828314     DOI: 10.1016/j.bbrc.2020.06.120

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  LncRNA MEG3 inhibits retinoblastoma invasion and metastasis by inducing β-catenin degradation.

Authors:  Yali Gao; Xiaona Chen; Jun Zhang
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

2.  LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting miR-155-5p.

Authors:  Xiancheng Han; Jing Liu; Yongguo Liu; Linkai Mou; Chunlong Li
Journal:  Cancer Manag Res       Date:  2021-06-01       Impact factor: 3.989

Review 3.  Perspectives on miRNAs Targeting DKK1 for Developing Hair Regeneration Therapy.

Authors:  Dimitri Papukashvili; Nino Rcheulishvili; Cong Liu; Fengfei Xie; Deependra Tyagi; Yunjiao He; Peng George Wang
Journal:  Cells       Date:  2021-10-30       Impact factor: 6.600

4.  Long noncoding RNA NR2F1-AS1 plays a carcinogenic role in gastric cancer by recruiting transcriptional factor SPI1 to upregulate ST8SIA1 expression.

Authors:  Fang Zuo; Yong Zhang; Jianting Li; Shaoxiang Yang; Xiaolu Chen
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Four Autophagy-Related Long Noncoding RNAs Provide Coexpression and ceRNA Mechanisms in Retinoblastoma through Bioinformatics and Experimental Evidence.

Authors:  He Ren; Xiaoyu Guo; Fang Li; Qinyun Xia; Zhen Chen; Yiqiao Xing
Journal:  ACS Omega       Date:  2021-11-29

6.  LINC-DUBR Suppresses Malignant Progression of Ovarian Cancer by Downregulating miR-107 to Induce SMAC Expression.

Authors:  Zhehui Han; Dan Li; Yun Yang; Hong Zhang
Journal:  J Healthc Eng       Date:  2022-03-03       Impact factor: 2.682

Review 7.  Drug Discovery of DKK1 Inhibitors.

Authors:  Hewen Jiang; Zongkang Zhang; Yuanyuan Yu; Hang Yin Chu; Sifan Yu; Shanshan Yao; Ge Zhang; Bao-Ting Zhang
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

8.  Long non‑coding RNA TTN‑AS1 regulates the proliferation, invasion and migration of triple‑negative breast cancer by targeting miR‑211‑5p.

Authors:  Erhu Sun; Xiaofeng Liu; Cheng Lu; Kangsheng Liu
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.